系统性硬化症患者间质性肺病进展的预测:SPAR模型
本研究基于两个独立前瞻性队列,纳入符合2013年美国风湿病学会/欧洲抗风湿病联盟标准、基线HRCT诊断轻度间质性肺病且无肺动脉高压或气流阻塞的系统性硬化症患者,在推导队列建立间质性肺病进展的预测模型并在多国验证队列验证。6分钟步行试验后SpO2较低和曾有 arthritis 被确定为两个队列中独立的预测因素,SPAR模型将预测率从25.5%提高至91.7%,AUC(95%CI)为0.83(0.73至0.93)。
要点
- 6分钟步行试验后SpO2较低和曾有 arthritis 是系统性硬化症轻度间质性肺病进展的独立预测因素。
- 6分钟步行试验后SpO2预测间质性肺病进展的最佳截断值为94%。
- SPAR模型将间质性肺病进展的预测率从25.5%提高至91.7%,AUC(95%CI)为0.83(0.73至0.93)。
核心结论
- 基于证据的SPAR预测模型可能有助于临床实践中对轻度系统性硬化症相关间质性肺病患者进行风险分层,并有助于未来临床试验设计的队列富集。
研究设计与样本
- 观察性研究,纳入来自两个独立前瞻性队列的系统性硬化症患者,所有患者符合2013年美国风湿病学会/欧洲抗风湿病联盟标准,基线经高分辨率计算机断层扫描诊断轻度间质性肺病,有基线和至少1次年度随访肺功能检查,且无并发肺动脉高压或气流阻塞。
主要发现
- 推导队列98例中25例、验证队列117例中25例系统性硬化症患者出现间质性肺病进展;6分钟步行试验后SpO2较低和曾有 arthritis 在两个队列中均被确定为间质性肺病进展的独立预测因素;6分钟步行试验后SpO2预测间质性肺病进展的最佳截断值经受试者工作特征曲线分析确定为94%。
关键数值与推荐
- 间质性肺病进展定义为随访1年时用力肺活量(FVC)%相对下降≥15%,或FVC%下降≥10%且一氧化碳弥散量%下降≥15%;SPAR模型结合6分钟步行试验后SpO2和 arthritis 两个预测因素,将预测率从25.5%提高至91.7%,AUC(95%CI)为0.83(0.73至0.93)。
临床怎么用
- 原文结论认为SPAR预测模型可能有助于临床实践中对轻度系统性硬化症相关间质性肺病患者进行风险分层,并有助于未来临床试验设计的队列富集。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To identify the predictive clinical characteristics and establish a prediction model for the progression of mild interstitial lung disease (ILD) in patients with systemic sclerosis (SSc). METHODS: Patients with SSc from two independent prospective cohorts were included in this observational study. All patients fulfilled the 2013 American College of Rheumatology/European League Against Rheumatism criteria, had mild ILD at baseline diagnosed by High-Resolution Computed Tomography (HRCT), available baseline and ≥1 annual follow-up pulmonary function tests and no concomitant pulmonary hypertension or airflow obstruction. ILD progression was defined as a relative decrease in forced vital capacity (FVC)%≥15%, or FVC%≥10% combined with diffusing capacity for carbon monoxide %≥15% at 1-year follow-up. Candidate predictors for multivariate logistic regression were selected by expert opinion based on clinical significance. A prediction model for ILD progression was established in the derivation cohort and validated in the multinational validation cohort. RESULTS: A total of 25/98 and 25/117 patients with SSc showed ILD progression in the derivation cohort and the validation cohort, respectively. Lower SpO2 after 6 min walk test (6MWT) and arthritis ever were identified as independent predictors for ILD progression in both cohorts. The optimal cut-off value of SpO2 after 6MWT for predicting ILD progression was determined as 94% by receiver operating characteristic curve analysis. The derived SPAR model combining both predictors (SPO2 and ARthritis) increased the prediction rate from 25.5% to 91.7% with an area under the curve (95% CI) of 0.83 (0.73 to 0.93). CONCLUSIONS: The evidence-based SPAR prediction model developed in our study might be helpful for the risk stratification of patients with mild SSc-ILD in clinical practice and cohort enrichment for future clinical trial design.
引用
- Wu W, Jordan S, Becker MO, et al. Prediction of progression of interstitial lung disease in patients with systemic sclerosis: the SPAR model. Ann Rheum Dis. 2018. PMID: 29875097. doi:10.1136/annrheumdis-2018-213201
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。